Seeking Alpha

Adam Gefvert, CFA

 
View as an RSS Feed
View Adam Gefvert, CFA's Comments BY TICKER:
Latest  |  Highest rated
  • Ampio Pharmaceuticals: Anywhere But Straight Out Of Isolagen's Playbook [View article]
    The Banker wrote a short piece yesterday that caused the stock to drop 25%.

    In response, AMPE has launched everything but the kitchen sink. There have been 4 Bullish AMPE Seeking Alpha articles, a response by management, and PR wire and Marketwatch letters out about a "short selling conspiracy". And as I write this, the stock has rebounded a whopping...5%.

    No Seeking Alpha AMPE bull owns any shares of AMPE, except one, Timeless Poverty. Nuff said.
    Dec 16 10:40 AM | Likes Like |Link to Comment
  • Retail Speculators Getting Amped On Ampio Pharmaceuticals [View article]
    To fellow AMPE shortsellers:

    The Banker wrote a short piece yesterday that caused the stock to drop 25%.

    In response, AMPE has thrown everything but the kitchen sink at us. There have been 4 Bullish AMPE Seeking Alpha articles, a response by management, and PR wire and Marketwatch letters out about a "short selling conspiracy". And the stock has rebounded a whopping...3%.

    No Seeking Alpha AMPE bull owns any shares of AMPE, except one, Timeless Wealth. Nuff said.
    Dec 16 10:29 AM | Likes Like |Link to Comment
  • Ampio's Shareholders Suffer As The Shorts Target Shares [View article]
    Whenever a stock tumbles by this amount, one test to see if it is really worth the price, is to watch insider action. If they are buying shares, then that's an indication it's worth it. If they don't buy any shares at these depressed prices, you have to wonder why.
    Dec 16 09:28 AM | Likes Like |Link to Comment
  • 4 Reasons Inhibitex Is No Longer A Good Buy [View article]
    Whoa! I sold too soon on the way up, covered too soon on the way down. This is a great day for INHX longs if you still think there's potential, you have an opportunity to buy at a great price.
    Dec 16 09:15 AM | Likes Like |Link to Comment
  • Why Diamond Foods' Late Director Shouldn't Have Been On The Audit Committee [View article]
    Now there's an SEC investigation on DMND. Do you guys understand now the relevancy of the suicide and this discussion? Or do you still think it's irrelevant?
    Dec 15 11:03 AM | Likes Like |Link to Comment
  • Retail Speculators Getting Amped On Ampio Pharmaceuticals [View article]
    Management has been dipping their toes in all kinds of schemes for a long time. Donald Wingerter, Michael Macaluso, and David Bar-Or were the only 3 executives that started DMI Lifesciences. Wingerter and Macaluso were running other companies while DMI Lifesciences was going on, so they're basically just entrepreneurs/salesmen. They are very talented no doubt, for creating a $200 million company out of thin air. There are a lot of suckers out there. Good luck to you. I think the clearest reason to get out of this stock is that the smart money is in fact short AMPE. I've spoken to several hedge fund managers who say this is the best short they've ever seen, and are heavily short. And like I said, there are no hedge fund managers or mutual funds that are long. But I'm only saying this to help Seeking Alpha readers and to hurry along my short profits. All I have to do is wait till January when the planned mass selling will happen from Ampio, Ampio's management, and Genesis.
    Dec 14 07:22 PM | Likes Like |Link to Comment
  • Retail Speculators Getting Amped On Ampio Pharmaceuticals [View article]
    You have a link to confirm this? Also, Ampio has only been around for 1.5 years. DMI Life Sciences was the shell company, this is a reverse merger.
    Dec 14 05:42 PM | Likes Like |Link to Comment
  • Retail Speculators Getting Amped On Ampio Pharmaceuticals [View article]
    Getting handed to them? This stock was above $7 just yesterday until Banker's article came out.
    Dec 14 03:54 PM | Likes Like |Link to Comment
  • Retail Speculators Getting Amped On Ampio Pharmaceuticals [View article]
    This is the best, most obvious short I've ever seen. I don't mind the stock having legs now, because AMPE filed to sell 10 million shares for the company, 1 million shares for the executives compensation, and the Genesis fund will sell 1.5 million shares in January. After all that happens, we'll see where the stock is trading.
    Dec 14 03:38 PM | Likes Like |Link to Comment
  • Spectrum's Fusilev Sales Will Suffer As Leucovorin Shortage Is Eliminated [View article]
    I think academic is the wrong word. Not sure what's the word I'm looking for but study, research, factual, and informational purposes are better ;)
    Dec 13 12:49 PM | Likes Like |Link to Comment
  • AEterna Zentaris And Keryx: Phase 3 Set For Success; Takeover Likely [View article]
    Well, I'm just looking for info. But seeing that Jeremy only has 25 comments and 82 articles, responding to feedback is probably not his style.
    Dec 13 12:39 PM | Likes Like |Link to Comment
  • AEterna Zentaris And Keryx: Phase 3 Set For Success; Takeover Likely [View article]
    Thanks for your opinion.

    "It is clear that AEZS has tremendous upside potential and that Perofisine data is extremely positive."

    What exactly is extremely positive about the Perifosine data? You have a lot of facts in this report and talk about how many people want to buy the stock, but you don't make clear what part of the testing data you think is positive.

    You do mention 10% less patients died than expected, is that the positive data you're referring to?
    Dec 13 09:24 AM | Likes Like |Link to Comment
  • Smart Money Betting On Ampio Pharmaceuticals [View article]
    I guess this article's title must be a joke. Smart money avoids this stock like no other. No biotech or hedge funds own it, and no institution or mutual fund owns over 1% of the outstanding shares. That's extremely rare for a non-penny stock. You can check it on Yahoo Finance.
    Dec 12 08:30 PM | Likes Like |Link to Comment
  • Spectrum's Fusilev Sales Will Suffer As Leucovorin Shortage Is Eliminated [View article]
    My report isn't a "news flash", and it also isn't discussing everything under the sun about Spectrum. It's just a targeted academic study about Leucovorin and how its shortage could be coming to an end, which is going to be negative for Spectrum in my opinion.
    Dec 12 09:19 AM | Likes Like |Link to Comment
  • Why Perifosine Phase 3 Trials Will Likely Fail [View article]
    It's data dredging because even though originally they were going to use 381 patients for the study, they used 25 colon cancer patients because they had the best reaction to the drug. I don't think they had planned on doing it this way in the first place, correct me if I'm wrong. Then only adding 13 more patients isn't enough for solid proof that the drug has high efficacy.
    Dec 11 08:08 PM | Likes Like |Link to Comment
COMMENTS STATS
1,424 Comments
681 Likes